The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study.

Autor: Martínez-Pinteño A; Department of Basic Clinal Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain., Mezquida G; Department of Basic Clinal Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Barcelona, Spain; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address: mezquida@clinic.cat., Bioque M; Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Barcelona, Spain; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medicine, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain., López-Ilundain JM; Department of Basic Clinal Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Departamento de Psiquiatría, Complejo Hospitalario de Navarra, Insituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Navarra, Spain., Andreu-Bernabeu Á; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain., Zorrilla I; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Universidad del País Vasco/Euskal Herriko Unibertsitatea, Spain; Department of Psychiatry, Araba University Hospital, Bioaraba Research Institute, Vitoria-Gasteiz, Spain., Mané A; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Autonomous University of Barcelona, Spain., Rodríguez-Jiménez R; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; CogPsy Group, Universidad Complutense de Madrid (UCM), Madrid, Spain., Corripio I; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Psychiatry Department, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Department of Psychiatry and Forensic Medicine, Barcelona, Spain., Sarró S; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; FIDMAG Germanes Hospitalàries Research Foundation, Dr Pujadas, 38, 08830, Sant Boi de Llobregat, Barcelona, Spain., Ibáñez Á; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain., Usall J; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, University of Barcelona, Barcelona, Spain., Rivero O; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Biomedical Research Institute INCLIVA, Fundación Investigación Hospital Clínico de Valencia, Valencia, Spain; Departament of Genetics, Universitat de València, Valencia, Spain., Gassó P; Department of Basic Clinal Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Leza JC; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Department of Pharmacology & Toxicology, School of Medicine, University Complutense (UCM), IIS Imas12, IUIN, Madrid, Spain., Cuesta MJ; Departamento de Psiquiatría, Complejo Hospitalario de Navarra, Insituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Navarra, Spain., Parellada M; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain., González-Pinto A; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Universidad del País Vasco/Euskal Herriko Unibertsitatea, Spain; Department of Psychiatry, Araba University Hospital, Bioaraba Research Institute, Vitoria-Gasteiz, Spain., Berrocoso E; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; Neuropsychopharmacology & Psychobiology Research Group, Psychobiology Area, Department of Psychology, University of Cádiz, Puerto Real (Cádiz), Spain; Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain., Mas S; Department of Basic Clinal Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address: sergimash@ub.edu., Bernardo M; Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Barcelona, Spain; Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medicine, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Jazyk: angličtina
Zdroj: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2022 Apr; Vol. 57, pp. 105-117. Date of Electronic Publication: 2022 Feb 24.
DOI: 10.1016/j.euroneuro.2022.02.003
Abstrakt: Neurotrophins have been proposed to be involved in biological mechanisms which might underlie different clinical outcomes in schizophrenia. The aims of the present study were to examine the BDNF/NGF plasma levels in a cohort of first-episode schizophrenia (FES) patients in remission as potential biological predictors of relapse; to study the associations between these neurotrophins and the symptomatology severity through different stages after a FES in two independent cohorts. 2EPs-Cohort: 69 first-episode in clinical remission were included. BDNF/NGF plasma levels and symptom severity were measured at enrollment and at 3-year or at the time of the second episode/relapse. FLAMM-PEPs-Cohort: 65 first-episodes were also included. BDNF/NGF and symptom severity were obtained at enrollment and 2-year follow-up. Symptomatology was assessed with the Marder-PANSS-Factor scores. Plasma neurotrophins did not differ significantly over time and neither BDNF/NGF were predictors of relapse. Besides, in remission stages, baseline BDNF levels showed significant correlations with both positive and negative symptoms (p<0.05); NGF, with negative symptomatology (p<0.01). Similarly, in the FLAMM-PEPs-Cohort, baseline BDNF/NGF levels showed significant correlations with negative symptoms (and not positive symptomatology) at follow-up (p<0.05). In both cohorts, lower levels correlated with higher symptom severity. Findings did not support a role for BDNF/NGF plasma levels as biomarkers of relapse in FES patients. Nevertheless, baseline BDNF/NGF may lead to be considered potentially useful biomarkers of long-term severity in schizophrenia and of the underlying illness traits, specially of negative symptomatology severity. More longitudinal studies in FES samples and adding a control group are warranted to replicate these findings.
Competing Interests: Conflict of Interest Dr. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda. Pilar A Sáiz, has been a consultant to and/or has received honoraria or grants from Adamed, CIBERSAM, European Comission, Government of the Principality of Asturias (PCTI-2018–2022 IDI/2018/235), Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional sobre Drogas and Servier. The rest of authors have declared that there are no conflicts of interest in relation to the subject of this study.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: